Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice
about
Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitroHighly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegenerationEffect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferretsThe Influenza Virus Polymerase Complex: An Update on Its Structure, Functions, and Significance for Antiviral Drug DesignInfluenza neuraminidase inhibitors: antiviral action and mechanisms of resistanceA review of mathematical models of influenza A infections within a host or cell culture: lessons learned and challenges aheadWhat is the optimal therapy for patients with H5N1 influenza?Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A virusesI222 Neuraminidase mutations further reduce oseltamivir susceptibility of Indonesian Clade 2.1 highly pathogenic Avian Influenza A(H5N1) virusesOseltamivir Prophylaxis Reduces Inflammation and Facilitates Establishment of Cross-Strain Protective T Cell Memory to Influenza VirusesProgress of small molecular inhibitors in the development of anti-influenza virus agents.Model-based simulation and prediction of an antiviral strategy against influenza A infection.In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus.Synergistic combinations of favipiravir and oseltamivir against wild-type pandemic and oseltamivir-resistant influenza A virus infections in mice.Continuing challenges in influenza.MegaRibavirin aerosol for the treatment of influenza A virus infections in miceSusceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model.Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro.Drugs in development for influenza.Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A virusesNeuraminidase inhibitor sensitivity and receptor-binding specificity of Cambodian clade 1 highly pathogenic H5N1 influenza virusCombinations of L-NG-monomethyl-arginine and oseltamivir against pandemic influenza A virus infections in mice.ANTIVIRAL COMPOUNDS IN THE PIPELINE TO TACKLE H1N1 INFLUENZA INFECTION.Combination chemotherapy for influenza.Antiviral strategies for pandemic and seasonal influenzaCombinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice.Newer influenza antivirals, biotherapeutics and combinations.Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice.Characterization of the anti-influenza activity of the Chinese herbal plant Paeonia lactiflora.Developing new antiviral agents for influenza treatment: what does the future hold?Competitive fitness of oseltamivir-sensitive and -resistant highly pathogenic H5N1 influenza viruses in a ferret model.Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice.Animal Models for Influenza Virus Pathogenesis and Transmission.How to approach and treat viral infections in ICU patientsMast cell-induced lung injury in mice infected with H5N1 influenza virus.Depressed Hypoxic and Hypercapnic Ventilatory Responses at Early Stage of Lethal Avian Influenza A Virus Infection in Mice.Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever virusesEfficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective studyA novel small-molecule inhibitor of influenza A virus acts by suppressing PA endonuclease activity of the viral polymerase.Combinations of Oseltamivir and T-705 Extend the Treatment Window for Highly Pathogenic Influenza A(H5N1) Virus Infection in Mice
P2860
Q21142648-3509BCFF-D61B-450F-8BBB-7B6BD24A3CD2Q24649627-F917A1A1-E66D-4319-BBE0-2DD409FA3D35Q27314689-C009F7C9-4BD3-4321-A22B-CBF1FFBC9D4BQ28071809-A77CDD82-2E25-4DC9-9E14-A7A4B8411D55Q28282405-9DD8AADE-E443-4032-AE7E-9B0E26842406Q28382972-A98B47C3-6388-4999-826B-886C9D8CBE18Q28475630-3298B123-8C34-41A0-82B6-86AF3D164075Q28479036-169C037F-31CE-47A4-9D47-6F4F8974104DQ28533778-413111A9-230D-47F7-93C8-A3641EF3B5FFQ28548477-FFF99B5A-812D-4F7E-833B-00F4C99428E6Q30234943-0F7207AB-E881-47C1-8D99-4E6DFE10D389Q30352246-2005E7BC-A50D-420D-9A47-2762BD8AABACQ30356466-B1ACA71B-55D4-4ECF-A453-18B9FAEE2A19Q30359363-4C601853-3CA5-4356-B312-A448753B1D8DQ30363190-F313B701-AD5E-408C-B1E8-6BB32450F22AQ30367819-FF145B02-058E-45D9-8B3B-6012C247B1D4Q30376004-B779E477-9537-4FED-AB5C-C208657BF29AQ30379095-538672F2-6D51-424E-966D-FCE6610D73DEQ30391218-D570A354-C056-4BF6-AEA0-918BEE1909A6Q30394067-ABF025C2-8A33-44CD-BCF5-E2B4C1521A84Q30400058-B8957FA9-448F-4FF5-9C9C-D1E39128E7AFQ30401138-ADB3058D-9825-4435-9464-FBF97E507BDEQ30404586-09BBE409-8A25-49F7-BFE3-E55BC2BFC2FFQ30408112-1FC216E8-07EF-4326-8224-4D0C08AA0E1BQ30408116-0B056ECC-CA15-4F32-8951-EC2C73BBCA68Q30414428-BFE79830-93CE-4C7B-8AD6-C06D1BD91164Q30456363-22B71136-F8DE-4888-8E12-E7DD4AA3C15CQ33559151-79A4A7A8-FA38-4C8C-9A00-B331E16174FDQ33584810-F56DF387-D5C0-46D7-9C52-42FE8AFFFDE2Q34015113-FBB8DDC3-FCFC-4F3B-87D6-F1157205B63CQ34046111-7657396E-076B-46F3-A71F-349ACA0E5E97Q34159076-B48975E5-BB7E-4320-B08A-16919B81CD0AQ34714853-54FC9EBE-70C1-4620-AE15-72ED21BBD31FQ34894660-7AC2366A-6A35-4AB2-AAF6-0DAC4442FC9CQ35826260-E09C70D2-AACB-48BF-BE7D-8F4A81EC7967Q35903861-5C3B3A65-4D12-4E49-884F-8D1AB124760BQ36494323-A195DA7E-7DC7-4B63-AB4D-1BC9E3DE942EQ36566014-D08B3F5C-FCE1-40E0-BA6A-FA30C97CC359Q36666497-1DDF1917-34ED-4DE4-8413-49FB95EBED67Q36934209-60A28671-21FC-435D-A606-BC6BF1760E4F
P2860
Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Oseltamivir-ribavirin combinat ...... luenza virus infection in mice
@en
type
label
Oseltamivir-ribavirin combinat ...... luenza virus infection in mice
@en
prefLabel
Oseltamivir-ribavirin combinat ...... luenza virus infection in mice
@en
P2093
P2860
P356
P1476
Oseltamivir-ribavirin combinat ...... luenza virus infection in mice
@en
P2093
Adrianus C M Boon
Natalia A Ilyushina
Neziha Yilmaz
P2860
P304
P356
10.1128/AAC.01579-07
P407
P577
2008-08-25T00:00:00Z